CoChat
Sign Up
Cited by 8Mitochondrial Function and PathologyAlzheimer's disease research and treatmentsAutophagy in Disease and Therapy

Mitochondrial Function in Alzheimer’s Disease: Focus on Astrocytes

Open access
Lampinen, Riikka, Belaya, Irina, Boccuni, Isabella, Malm, Tarja, Kanninen, Katja M.·2018·Astrocyte - Physiology and Pathology
DOI 10.5772/intechopen.71825
Open this paper in CoChat — free accountOpen PDF

Abstract

The brain is one of the most energy-requiring organs in the human body. Mitochondria not only generate this energy, but are centrally involved critical cellular functions including maintenance of calcium homeostasis, synthesis of biomolecules, and cell signaling. Even though neurons and astrocytes preferentially use different energy substrates and metabolic pathways, these two cell types are intricately linked in their energy metabolism. Recently it has become clear that astrocytes have a key role in the regulation and support of the neuronal mitochondrial quality control, yet several questions remain unanswered to fully understand the mechanisms of mitochondrial function, transport, turnover and degradation in astrocytes. Alzheimer’s disease is the most common neurodegenerative disorder, the exact mechanisms of which remain incompletely understood. The fact that astrocytic mitochondrial dysfunction is an early event in the pathogenesis of Alzheimer’s disease suggests that more research on mitochondrial function and impairment is required in the hopes of disease alleviation in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5772/intechopen.71825

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mitochondrial deterioration in astrocytes occurs early in AD development.

    “mitochondrial deterioration in astrocytes occurs early in the disease development”

    From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [12]

    Section 7 reports mitochondrial dysfunction in AD astrocytes. Section 8 says mitochondrial oxidative damage is an early event in AD, but does not specify astrocytes; Section 6 describes early astrocyte changes in mouse models without identifying them as mitochondrial deterioration. The source therefore supports the two elements separately, not their claimed timing together. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Astrocytes play a fundamental role in AD pathology.

    “Also, although astrocytes play a fundamental role in AD pathology12, little is known about APOE4 effect on their mitochondria.”

    From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [12]

  • Changes in mitochondrial dynamics and mitochondrial dysfunction are recognized as hallmarks of AD.

    “Changes in mitochondrial dynamics and mitochondrial dysfunction are recognized as hallmarks of AD”

    From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [12]

  • The mechanism of mitochondrial deterioration in astrocytes in AD is vague.

    “the mechanism is vague12.”

    From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [12]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 121

  1. Mergenthaler P, Lindauer U, Dienel GA, et al. Sugar for the brain: The role of glucose in physiological and pathological brain function. Trends in Neurosciences. 2013;36(10): 587-597
  2. Howarth C, Gleeson P, Atwell D. Updated energy budgets for neural computation in the neocortex and cerebellum. Journal of Cerebral Blood Flow & Metabolism. 2012;32(7): 1222-1232
  3. Magistreti PJ. Role of glutamate in neuron-glia metabolic coupling. The American Journal of Clinical Nutrition. 2009;90(3):875-880
  4. Bélanger M, Allaman I, Magistreti P. Brain energy metabolism: Focus on astrocyte-neu- ron metabolic cooperation. Cell Metabolism. 2011;14(6):724-738
  5. Fu W, Jhamandas JH. Role of astrocytic glycolytic metabolism in Alzheimer's disease pathogenesis. Biogerontology. 2014;15(6):579-586
  6. Bolaños JP, Almeida A, Moncada S. Glycolysis: A bioenergetic or a survival pathway? Trends in Biochemical Sciences. 2010;35(3):145-149
  7. Suzuki A, Stern S, Bozdagi O, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell. 2011;144(5):810-823
  8. Rose J, Brian C, Woods J, et al. Mitochondrial dysfunction in glial cells: Implications for neuronal homeostasis and survival. Toxicology. 2017;391:109-115
  9. Walls AB, Heimbürger CM, Bouman SD, et al. Robust glycogen shunt activity in astro- cytes: Efects of glutamatergic and adrenergic agents. Neuroscience. 2009;158(1):284-292
  10. Obel LF, Müller MS, Walls AB, et al. Brain glycogen-new perspectives on its metabolic function and regulation at the subcellular level. Frontiers in Neuroenergetics. 2012;4: 1-15
  11. Almeida A, Moncada S, Bolaños JP. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nature Cell Biology. 2004;6(1): 45-51
  12. Voutsinos-Porche B, Bonvento G, Tanaka K, et al. Glial glutamate transporters mediate a functional metabolic crosstalk between neurons and astrocytes in the mouse developing cortex. Neuron. 2003;37(2):275-286
  13. Pellerin L, Magistreti PJ. Glutamate uptake into astrocytes stimulates aerobic gly- colysis: A mechanism coupling neuronal activity to glucose utilization. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(22): 10625-10629
  14. Sagan L. On the origin of mitosing cells. Journal of Theoretical Biology. 1967;14(3):255-274
  15. Held NM, Houtkooper RH. Mitochondrial quality control pathways as determinants of metabolic health. BioEssays. 2015;37(8):867-876
  16. Duchen MR. Mitochondria and calcium: From cell signalling to cell death. The Journal of Physiology. 2000;529:57-68
  17. Giorgi C, Baldassari F, Bononi A, et al. Mitochondrial Ca(2+) and apoptosis. Cell Calcium. 2012;52(1):36-43
  18. Raps SP, Lai JC, Herz L, et al. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Research. 1989;493(2):398-401
  19. Ziech D, Franco R, Georgakilas AG, et al. The role of reactive oxygen species and oxi- dative stress in environmental carcinogenesis and biomarker development. Chemico- Biological Interactions. 2010;188(2):334-339
  20. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and efect of hyperbaric oxygen. The Biochemical Journal. 1973;134(3):707-716
  21. Zorov DB, Filburn CR, Kloz LO, et al. Reactive oxygen species (ROS)-induced ROS release: A new phenomenon accompanying induction of the mitochondrial permeabil- ity transition in cardiac myocytes. The Journal of Experimental Medicine. 2000;192(7): 1001-1014
  22. Hara Y, Yuk F, Puri R, et al. Presynaptic mitochondrial morphology in monkey pre- frontal cortex correlates with working memory and is improved with estrogen treat- ment. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(1):486-491
  23. Verkhratsky A, Olabarria M, Noristani HN, et al. Astrocytes in Alzheimer's disease. Neurotherapeutics. 2010;7(4):399-412
  24. Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathologica. 2010;119(1):7-35
  25. Ogata K, Kosaka T. Structural and quantitative analysis of astrocytes in the mouse hip- pocampus. Neuroscience. 2002;113(1):221-233
  26. Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: Redeining the func- tional architecture of the brain. Trends in Neurosciences. 2003;26(10):523-530
  27. Lovat D, Sonnewald U, Waagepetersen HS, et al. The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. The Journal of Neuroscience. 2007;27(45):12255-12266
  28. Acosta C, Anderson HD, Anderson C. Astrocyte dysfunction in Alzheimer disease. Journal of Neuroscience Research. 2017;95(12):2430-2447
  29. Jackson JG, Robinson MB. Reciprocal regulation of mitochondrial dynamics and calcium signaling in astrocyte processes. The Journal of Neuroscience. 2015;35(45):15199-15213
  30. Jackson JG, O'Donnell JC, Takano H, et al. Neuronal activity and glutamate uptake decrease mitochondrial mobility in astrocytes and position mitochondria near gluta- mate transporters. The Journal of Neuroscience. 2014;34(5):1613-1624
  31. Cagalinec M, Saiulina D, Liiv M, et al. Principles of the mitochondrial fusion and ission cycle in neurons. Journal of Cell Science. 2013;126(10):2187-2197
  32. Jeong SY, Seol DW. The role of mitochondria in apoptosis. BMB Reports. 2008;41(1):11-22
  33. Lionaki E, Markaki M, Palikaras K, et al. Mitochondria, autophagy and age-associated neurodegenerative diseases: New insights into a complex interplay. Biochimica et Biophysica Acta. 2015;1847(11):1412-1423
  34. Amadoro G, Corseti V, Florenzano F, et al. Morphological and bioenergetic demands underlying the mitophagy in post-mitotic neurons: The pink-parkin pathway. Frontiers in Aging Neuroscience. 2014;6:18
  35. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Research. 2005;8(1):3-5
  36. Kissova I, Deieu M, Manon S, et al. Uth1p is involved in the autophagic degradation of mitochondria. The Journal of Biological Chemistry. 2004;279(37):39068-39074
  37. Narendra DP, Youle RJ. Targeting mitochondrial dysfunction: Role for PINK1 and Parkin in mitochondrial quality control. Antioxidants & Redox Signaling. 2011;14(10): 1929-1938
  38. Cai Q, Lu L, Tian JH, et al. Snapin-regulated late endosomal transport is critical for ei- cient autophagy-lysosomal function in neurons. Neuron. 2010;68(1):73-86
  39. Hayakawa K, Esposito E, Wang X, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535(7613):551-555
  40. Berridge MV, Schneider RT, McConnell MJ. Mitochondrial transfer from astrocytes to neurons following ischemic insult: Guilt by association? Cell Metabolism. 2016;24(3): 376-378
  41. Derouiche A, Haseleu J, Korf HW. Fine astrocyte processes contain very small mito- chondria: Glial oxidative capability may fuel transmiter metabolism. Neurochemical Research. 2015;40(12):2402-2413
  42. Mayeux R. Early Alzheimer's disease. The New England Journal of Medicine. 2010;362(23): 2194-2201
  43. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease patho- genesis. Biological Psychiatry. 2015;77(1):43-51
  44. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(10):1-10
  45. Demetrius LA, Driver J. Alzheimer's as a metabolic disease. Biogerontology. 2013;14(6): 641
  46. Lee J, Han P. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Experimental Neurobiology. 2013;22(2):84-95
  47. Jones VC, Atkinson-dell R, Verkhratsky A, et al. Aberrant iPSC-derived human astro- cytes in Alzheimer's disease. Cell Death and Disease. 2017;8(3):e2696
  48. Liao M, Muratore CR, Gierahn TM, et al. Single-cell detection of secreted Aβ and sAPPα from human IPSC-derived neurons and astrocytes. The Journal of Neuroscience. 2016;36(5):1730-1746
  49. Rodríguez-Arellano JJ, Parpura V, Zorec R, et al. Astrocytes in physiological aging and Alzheimer's disease. Neuroscience. 2016;323:170-182
  50. van Gijsel-Bonnello M, Baranger K, Benech P, et al. Metabolic changes and inlammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer's disease: Alleviation by pantethine. PLoS One. 2017;12(4):1-22
  51. Iram T, Trudler D, Kain D, et al. Astrocytes from old Alzheimer's disease mice are impaired in Aβ uptake and in neuroprotection. Neurobiology of Disease. 2016;96:84-94
  52. Olabarria M, Noristani HN, Verkhratsky A, et al. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia. 2010;58(7): 831-838
  53. Orre M, Kamphuis W, Osborn LM, et al. Isolation of glia from Alzheimer's mice reveals inlammation and dysfunction. Neurobiology of Aging. 2014;35(12):2746-2760
  54. Pomilio C, Pavia P, Gorojod RM, et al. Glial alterations from early to late stages in a model of Alzheimer's disease: Evidence of autophagy involvement in Aβ internaliza- tion. Hippocampus. 2016;26(2):194-210
  55. Hartlage-Rübsamen M, Zeitschel U, Apelt J, et al. Astrocytic expression of the Alzheimer's disease β-secretase (BACE1) is stimulus-dependent. Glia. 2003;41(2):169-179
  56. Oberheim NA, Takano T, Han X, et al. Uniquely hominid features of adult human astro- cytes. Journal of Neuroscience. 2009;29(10):3276-3287
  57. Pekny M, Wilhelmsson U, Pekna M. The dual role of astrocyte activation and reactive gliosis. Neuroscience Leters. 2014;565:30
  58. Zamanian JL, Xu L, Foo LC, et al. Genomic analysis of reactive astrogliosis. The Journal of Neuroscience. 2012;32(18):6391-6410
  59. Osborn LM, Kamphuis W, Wadman WJ, et al. Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease. Progress in Neurobiology. 2016;144:121-141
  60. Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Research Bulletin. 2017. pii: S0361-9230(17)30082-5 [Epub ahead of print]
  61. Cotrina ML, Nedergaard M. Astrocytes in the aging brain. Journal of Neuroscience Research. 2002;67(1):1-10
  62. Schipper H, Gupta A, Szarek W. Suppression of glial HO-1 activitiy as a potential neuro- therapeutic intervention in AD. Current Alzheimer Research. 2009;6(5):424-430
  63. Schubert D, Soucek T, Blouw B. The induction of HIF-1 reduces astrocyte activation by amyloid beta peptide. The European Journal of Neuroscience. 2009;29(7):1323-1334
  64. Cai Z, Cheng-Qun W, Zhou L. Astrocyte and Alzheimer's disease. Journal of Neurology. 2017;264(10):2068-2074
  65. Merlini M, Meyer E, Ulmann-Schuler A, et al. Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice. Acta Neuropathologica. 2011;122(3):293-311
  66. Lu W, Huang J, Sun S, et al. Changes in lactate content and monocarboxylate transporter 2 expression in Aβ₂₅₋₃₅-treated rat model of Alzheimer's disease. Neurological Sciences. 2015;36(6):871
  67. Kubik LL, Philbert MA. The role of astrocyte mitochondria in diferential regional sus- ceptibility to environmental neurotoxicants: Tools for understanding neurodegenera- tion. Toxicological Sciences. 2015;144(1):7-16
  68. Stephen T, Gupta-Agarwal S, Kitler JT. Mitochondrial dynamics in astrocytes. Biochemical Society Transactions. 2014;42(5):1302-1310
  69. Demetrius LA, Simon DK. The inverse association of cancer and Alzheimer's: A bioener- getic mechanism. Journal of the Royal Society Interface. 2013;10(82):20130006
  70. Slemmer JE, Shacka JJ, Sweeney MI, et al. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Current Medicinal Chemistry. 2008;15(4):404-414
  71. Kaminsky YG, Kosenko EA. Efects of amyloid-beta peptides on hydrogen peroxide- metabolizing enzymes in rat brain in vivo. Free Radical Research. 2008;42(6):564-573
  72. Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. The Journal of Neuroscience. 2004;24(2):565-575
  73. Kuchibhotla KV, Latarulo CR, Hyman BT, et al. Synchronous hyperactivity and intercel- lular calcium waves in astrocytes in Alzheimer mice. Science. 2009;323(5918):1211-1215
  74. Begley JG, Duan W, Chan S, et al. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. Journal of Neurochemistry. 1999;72(3):1030-1039
  75. Pagani L, Eckert A. Amyloid-Beta interaction with mitochondria. International Journal of Alzheimer's Disease. 2011;2011:925050
  76. Swerdlow RH. The neurodegenerative mitochondriopathies. Journal of Alzheimer's Disease. 2009;17(4):737-751
  77. Halliwell B. Reactive oxygen species and the central nervous system. Journal of Neuro- chemistry. 1992;59(5):1609-1623
  78. Sagara JI, Miura K, Bannai S. Maintenance of neuronal glutathione by glial cells. Journal of Neurochemistry. 1993;61(5):1672-1676
  79. Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mito- chondrial dysfunction in Alzheimer's disease. Journal of Neurochemistry. 2012;120(3): 419-429
  80. Rice AC, Keeney PM, Algarzae NK, et al. Mitochondrial DNA copy numbers in pyrami- dal neurons are decreased and mitochondrial biogenesis transcriptome signaling is dis- rupted in Alzheimer's disease hippocampi. Journal of Alzheimer's Disease. 2014;40(2): 319-330
  81. Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer's dis- ease. Journal of Neuroscience. 2001;21(9):3017-3023
  82. Fukui H, Moraes CT. The mitochondrial impairment, oxidative stress and neurodegen- eration connection: Reality or just an atractive hypothesis? Trends in Neurosciences. 2008;31(5):251-256
  83. Fu W, Shi D, Westaway D, et al. Bioenergetic mechanisms in astrocytes may contrib- ute to amyloid plaque deposition and toxicity. The Journal of Biological Chemistry. 2015;290(20):12504-12513
  84. Misko A, Jiang S, Wegorzewska I, et al. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. Journal of Neuroscience. 2010;30(12):4232-4240
  85. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmiter homeostasis and ammonia transfer. Journal of Neurochemistry. 2006;98(3):641-653
  86. Voloboueva LA, Suh SW, Swanson RA, et al. Inhibition of mitochondrial function in astrocytes: Implications for neuroprotection. Journal of Neurochemistry. 2007;102(4): 1383-1394
  87. Genda EN, Jackson JG, Sheldon AL, et al. Co-compartmentalization of the astroglial glutamate transporter, GLT-1, with glycolytic enzymes and mitochondria. The Journal of Neuroscience. 2011;31(50):18275-18288
  88. Sekar S, McDonald J, Cuyugan L, et al. Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiology of Aging. 2015;36(2):583-591
  89. Sarkar P, Zaja I, Bienengraeber M, et al. Epoxyeicosatrienoic acids pretreatment improves amyloid -induced mitochondrial dysfunction in cultured rat hippocampal astrocytes. AJP -Heart and Circulatory Physiology. 2014;306(4):475-484
  90. Lee H, Pancholi N, Esposito L, et al. Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PLoS One. 2012;7(1):e28033
  91. Tamagno E, Guglielmoto M, Aragno M, et al. Oxidative stress activates a positive feedback between the γ-and β-secretase cleavages of the β-amyloid precursor protein. Journal of Neurochemistry. 2008;104(3):683-695
  92. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: A systematic review and meta-analysis. PLoS One. 2015;10(4):e0123289
  93. Amanatkar HR, Papagiannopoulos B, Grossberg GT. Analysis of recent failures of dis- ease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies. Expert Review of Neurotherapeutics. 2017;17(1):7-16
  94. Reddy AP, Reddy PH. Mitochondria-targeted molecules as potential drugs to treat patients with Alzheimer's disease. Progress in Molecular Biology and Translational Science. 2017;146:173-201
  95. Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deicit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(34):14670-14675
  96. Wilkins HM, Morris HM. New therapeutics to modulate mitochondrial function in neurodegenerative disorders. Current Pharmaceutical Design. 2017;23(5):731-752
  97. Morris MC, Tangney CC, Wang Y, et al. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's & Dementia. 2015;11(9):1007-1014
  98. Chirles TJ, Reiter K, Weiss LR, et al. Exercise training and functional connectivity changes in mild cognitive impairment and healthy elders. Journal of Alzheimer's Disease. 2017; 57:845-856
  99. Van Cauwenberghe C, Vandendriessche C, Libert C, et al. Caloric restriction: Beneicial efects on brain aging and Alzheimer's disease. Mammalian Genome. 2016;27(7):300-319
  100. Martin B, Matson MP, Maudsley S. Caloric restriction and intermitent fasting: Two potential diets for successful brain aging. Ageing Research Reviews. 2006;5(3):332-353
  101. Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neu- rological disorders: Mechanisms of action and therapeutic opportunities. Brain and Behavior. 2014;4(2):108-122
  102. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inlammatory and neu- roprotective treatment for Alzheimer's disease. Advanced Drug Delivery Reviews. 2008;60(13):1463-1470
  103. Baum L, Lam CWK, Cheung SK, et al. Six-month randomized, placebo-controlled, dou- ble-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Journal of Clinical Psychopharmacology. 2008;28(1):110-113
  104. Pocernich CB, Buterield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. BBA -Molecular Basis of Disease. 2012;1822(5):625-630
  105. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB Journal. 2004;18(2):323-325
  106. Usoro OB, Mousa SA. Vitamin E forms in Alzheimer's disease: A review of contro- versial and clinical experiences. Critical Reviews in Food Science and Nutrition. 2010;50(5):414-419
  107. Ye CY, Lei Y, Tang XC, et al. Donepezil atenuates Aβ-associated mitochondrial dys- function and reduces mitochondrial Aβ accumulation in vivo and in vitro. Neuro- pharmacology. 2015;95:29-36
  108. Ng LF, Gruber J, Cheah IK, et al. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease. Free Radical Biology & Medicine. 2014;71:390-401
  109. Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31, a potential candidate for the treatment of Alzheimer's disease. Human Molecular Genetics. 2017;26(8):1483-1496
  110. Szeto H. Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents. The AAPS Journal. 2006;8(3):521-531
  111. Kim IK, Lee KJ, Rhee S, et al. Protective effects of Peroxiredoxin 6 overexpression on amyloid β-induced apoptosis in PC12 cells. Free Radical Research. 2013;47(10): 836-846
  112. Dragicevic N, Delic V, Cao C, et al. Cafeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells. Neuro- pharmacology. 2012;63(8):1368-1379
  113. Rege SD, Geetha T, Griin GD, et al. Neuroprotective efects of resveratrol in Alzheimer disease pathology. Frontiers in Aging Neuroscience. 2014;6:218
  114. Meng X, Wang M, Sun G, et al. Atenuation of Aβ25-35-induced parallel autophagic and apoptotic cell death by gypenoside XVII through the estrogen receptor-dependent activation of Nrf2/ARE pathways. Toxicology and Applied Pharmacology. 2014;279(1): 63-75
  115. Onyango IG, Dennis J, Khan SM. Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies. Aging and Disease. 2016;7(2):201-214
  116. East DA, Fagiani F, Crosby J, et al. PMI: A ΔΨm independent pharmacological regula- tor of mitophagy. Chemistry & Biology. 2014;21(11):1585-1596
  117. Cui M, Tang X, Christian WV, et al. Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1. The Journal of Biological Chemistry. 2010;285(15):11740-11752
  118. Manczak M, Kandimalla R, Fry D, et al. Protective efects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic dam- age in Alzheimer's disease. Human Molecular Genetics. 2016;25(23):5148-5166
  119. Xie N, Wang C, Lian Y, et al. Inhibition of mitochondrial ission atenuates Aβ-induced microglia apoptosis. Neuroscience. 2014;256:36-42
  120. Jang M, Jung S, Lee M, et al. Melatonin atenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neuroscience Leters. 2005;380(1-2):26-31
  121. Schitine C, Nogaroli L, Costa MR, et al. Astrocyte heterogeneity in the brain: From development to disease. Frontiers in Cellular Neuroscience. 2015;9:76

Cited by

Sorted by citations

Authors
Lampinen, R., Belaya, I., Boccuni, I., Malm, T., & Kanninen, K. M.
ORCID
Venue
Astrocyte - Physiology and Pathology
Publisher
InTech
Published
2018-03-21
DOI
10.5772/intechopen.71825
OpenAlex
W2790298397
Cited by
8
References
15
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1
FWCI
1.34
Type
book chapter
Language
en
Open access
Licence
Locations
  • InTech eBooks (publishedVersion, cc-by)
  • Åbo Akademi University Research Portal (publishedVersion)
  • UEF eRepo (University of Eastern Finland) (submittedVersion, cc-by)
  • BiblioBoard Library Catalog (Open Research Library) (submittedVersion, cc-by)
Funders
Academy of Finland
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
Alzheimer's disease, astrocytes, mitochondrial dysfunction, mitochondrial quality control, astrocyte-neuron metabolic coupling, brain energy metabolism, calcium homeostasis, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review